Beam Therapeutics (BEAM) Debt to Equity (2019 - 2025)
Beam Therapeutics (BEAM) has disclosed Debt to Equity for 7 consecutive years, with $0.0 as the latest value for Q4 2025.
- On a quarterly basis, Debt to Equity fell 80.86% to $0.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.0, a 80.86% decrease, with the full-year FY2025 number at $0.0, down 80.86% from a year prior.
- Debt to Equity was $0.0 for Q4 2025 at Beam Therapeutics, up from $0.0 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.17 in Q1 2021 to a low of $0.0 in Q3 2025.
- A 5-year average of $0.03 and a median of $0.02 in 2024 define the central range for Debt to Equity.
- Peak YoY movement for Debt to Equity: surged 330.79% in 2021, then crashed 88.38% in 2025.
- Beam Therapeutics' Debt to Equity stood at $0.05 in 2021, then tumbled by 51.12% to $0.02 in 2022, then tumbled by 55.89% to $0.01 in 2023, then rose by 4.05% to $0.01 in 2024, then crashed by 80.86% to $0.0 in 2025.
- Per Business Quant, the three most recent readings for BEAM's Debt to Equity are $0.0 (Q4 2025), $0.0 (Q3 2025), and $0.0 (Q2 2025).